Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Size: px

Start display at page:

Download "Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site"

Emmeline Sharp
6 years ago
Views:

1 Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or hematopoietic Primary malignant neoplasms, not lymphatic or hematopoietic Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site Leukemias and lymphomas Specific cancer type , Lung Cancer 174.xx, 175.0, Breast Cancer (warehouse) 185.xx Prostate Cancer 157.xx Pancreatic Cancer 153.xx, 154.0, Colon Cancer Supplementary Table 2. ICD-9-CM codes used to define active cancer Chemotherapy MS-DRGs MS-DRG MS-DRG Title 837 CHEMO W ACUTE LEUKEMIA AS SDX OR W HIGH DOSE CHEMO AGENT W MCC 838 CHEMO W ACUTE LEUKEMIA AS SDX W CC OR HIGH DOSE CHEMO AGENT 839 CHEMO W ACUTE LEUKEMIA AS SDX W/O CC/MCC 846 CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W MCC 847 CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 848 CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC Radiation therapy codes CPT code range Description Therapeutic Radiology: Treatment Planning Radiation Therapy Simulation Radiation Physics Services Stereotactic Radiosurgery (SRS) Planning and Delivery Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services Radiation Treatment IMRT Delivery Stereoscopic Imaging Guidance Neutron Therapy Radiation Therapy Management Proton Therapy Hyperthermia Treatment Brachytherapy

2 Chemotherapy J codes HCPCS Description Category J8510 Oral busulfan Cytotoxic J8520 Capecitabine, oral, 150 mg Cytotoxic J8521 Capecitabine, oral, 500 mg Cytotoxic J8530 Cyclophosphamide oral 25 MG Cytotoxic J8560 Etoposide oral 50 MG Cytotoxic J8561 Oral everolimus Cytotoxic J8562 Oral fludarabine phosphate Cytotoxic J8565 Gefitinib oral Cytotoxic J8600 Melphalan oral 2 MG Cytotoxic J8610 Methotrexate oral 2.5 MG Cytotoxic J8700 Temozolomide Cytotoxic J8705 Topotecan oral Cytotoxic J8999 Oral prescription drug chemo Cytotoxic J9000 Doxorubicin hcl injection Cytotoxic J9001 Doxorubicin hcl liposome inj Cytotoxic J9002 Doxil injection Cytotoxic J9010 Alemtuzumab injection Biologic J9015 Aldesleukin injection Biologic J9017 Arsenic trioxide injection Cytotoxic J9019 Erwinaze injection Biologic J9020 Asparaginase, NOS Biologic J9025 Azacitidine injection Cytotoxic J9027 Clofarabine injection Cytotoxic J9031 Bcg live intravesical vac Biologic J9033 Bendamustine injection Cytotoxic J9035 Bevacizumab injection Biologic J9040 Bleomycin sulfate injection Cytotoxic J9041 Bortezomib injection Cytotoxic J9042 Brentuximab vedotin inj Biologic J9043 Cabazitaxel injection Cytotoxic J9045 Carboplatin injection Cytotoxic J9047 Injection, carfilzomib, 1 mg Cytotoxic J9050 Carmustine injection Cytotoxic J9055 Cetuximab injection Biologic J9060 Cisplatin 10 MG injection Cytotoxic J9062 Cisplatin 50 MG injection Cytotoxic J9065 Inj cladribine per 1 MG Cytotoxic J9070 Cyclophosphamide 100 MG inj Cytotoxic J9080 Cyclophosphamide 200 MG inj Cytotoxic J9090 Cyclophosphamide 500 MG inj Cytotoxic J9091 Cyclophosphamide 1.0 grm inj Cytotoxic J9092 Cyclophosphamide 2.0 grm inj Cytotoxic J9093 Cyclophosphamide lyophilized Cytotoxic

3 J9094 Cyclophosphamide lyophilized Cytotoxic J9095 Cyclophosphamide lyophilized Cytotoxic J9096 Cyclophosphamide lyophilized Cytotoxic J9097 Cyclophosphamide lyophilized Cytotoxic J9098 Cytarabine liposome inj Cytotoxic J9100 Cytarabine hcl 100 MG inj Cytotoxic J9110 Cytarabine hcl 500 MG inj Cytotoxic J9120 Dactinomycin injection Cytotoxic J9130 Dacarbazine 100 mg inj Cytotoxic J9140 Dacarbazine 200 MG inj Cytotoxic J9150 Daunorubicin injection Cytotoxic J9151 Daunorubicin citrate inj Cytotoxic J9155 Degarelix injection Hormonal J9160 Denileukin diftitox inj Biologic J9165 Diethylstilbestrol injection Hormonal J9170 Docetaxel injection Cytotoxic J9171 Docetaxel injection Cytotoxic J9175 Elliotts b solution per ml Not J9178 Inj, epirubicin hcl, 2 mg Cytotoxic J9179 Eribulin mesylate injection Cytotoxic J9181 Etoposide injection Cytotoxic J9182 Etoposide injection Cytotoxic J9185 Fludarabine phosphate inj Cytotoxic J9190 Fluorouracil injection Cytotoxic J9200 Floxuridine injection Cytotoxic J9201 Gemcitabine hcl injection Cytotoxic J9202 Goserelin acetate implant Hormonal J9206 Irinotecan injection Cytotoxic J9207 Ixabepilone injection Cytotoxic J9208 Ifosfamide injection Cytotoxic J9209 Mesna injection Not J9211 Idarubicin hcl injection Cytotoxic J9212 Interferon alfacon-1 inj Biologic J9213 Interferon alfa-2a inj Biologic J9214 Interferon alfa-2b inj Biologic J9215 Interferon alfa-n3 inj Biologic J9216 Interferon gamma 1-b inj Biologic J9217 Leuprolide acetate suspension Hormonal J9218 Leuprolide acetate injection Hormonal J9219 Leuprolide acetate implant Hormonal J9225 Vantas implant Hormonal J9226 Supprelin LA implant Hormonal J9228 Ipilimumab injection Biologic J9230 Mechlorethamine hcl inj Cytotoxic J9245 Inj melphalan hydrochl 50 MG Cytotoxic J9250 Methotrexate sodium inj Cytotoxic

4 J9260 Methotrexate sodium inj Cytotoxic J9261 Nelarabine injection Cytotoxic J9262 Inj, omacetaxine mep, 0.01mg Cytotoxic J9263 Oxaliplatin Cytotoxic J9264 Paclitaxel protein bound Cytotoxic J9265 Paclitaxel injection Cytotoxic J9266 Pegaspargase injection Biologic J9268 Pentostatin injection Cytotoxic J9270 Plicamycin (mithramycin) inj Cytotoxic J9280 Mitomycin injection Cytotoxic J9290 Mitomycin 20 MG inj Cytotoxic J9291 Mitomycin 40 MG inj Cytotoxic J9293 Mitoxantrone hydrochl / 5 MG Cytotoxic J9300 Gemtuzumab ozogamicin inj Biologic J9302 Ofatumumab injection Biologic J9303 Panitumumab injection Biologic J9305 Pemetrexed injection Cytotoxic J9306 Injection, pertuzumab, 1 mg Biologic J9307 Pralatrexate injection Cytotoxic J9310 Rituximab injection Biologic J9315 Romidepsin injection Cytotoxic J9320 Streptozocin injection Cytotoxic J9328 Temozolomide injection Cytotoxic J9330 Temsirolimus injection Cytotoxic J9340 Thiotepa injection Cytotoxic J9350 Topotecan injection Cytotoxic J9351 Topotecan injection Cytotoxic J9354 Inj, ado-trastuzumab emt 1mg Biologic J9355 Trastuzumab injection Biologic J9357 Valrubicin injection Cytotoxic J9360 Vinblastine sulfate inj Cytotoxic J9370 Vincristine sulfate 1 MG inj Cytotoxic J9371 Inj, vincristine sul lip 1mg Cytotoxic J9375 Vincristine sulfate 2 MG inj Cytotoxic J9380 Vincristine sulfate 5 MG inj Cytotoxic J9390 Vinorelbine tartrate inj Cytotoxic J9395 Injection, Fulvestrant Hormonal J9400 Inj, ziv-aflibercept, 1mg Biologic J9600 Porfimer sodium injection Other J9999 Chemotherapy drug Cytotoxic Q2043 Provenge, 50 million autologous CD54+ Biologic cells Q2049 Lipodox 10 mg Cytotoxic Q2050 Doxil 10mg Cytotoxic Q0138 Ferumoxytol Not

5 Outpatient cancer surgeries Procedure code Code description Exc tr-ext mal+marg 0.5 cm/< Exc tr-ext mal+marg cm Exc tr-ext mal+marg cm Exc tr-ext mal+marg cm Exc tr-ext mal+marg cm Exc tr-ext mal+marg >4 cm Exc h-f-nk-sp mal+marg 0.5/< Exc s/n/h/f/g mal+mrg Exc s/n/h/f/g mal+mrg Exc s/n/h/f/g mal+mrg Exc s/n/h/f/g mal+mrg Exc s/n/h/f/g mal+mrg >4 cm Exc f/e/e/n/l mal+mrg 0.5cm< Exc f/e/e/n/l mal+mrg Exc f/e/e/n/l mal+mrg Exc f/e/e/n/l mal+mrg Exc f/e/e/n/l mal+mrg Exc f/e/e/n/l mal+mrg >4 cm Mohs 1 stage Mohs 2 stage Mohs 3 stage Mohs addl stage Mohs addl specimen Mohs 1 stage h/n/hf/g Mohs addl stage Mohs 1 stage t/a/l Mohs addl stage t/a/l Mohs surg addl block Partial mastectomy P-mastectomy w/ln removal Mast radical Mast rad urban type Mast mod rad Partial mastectomy P-mastectomy w/ln removal Mast radical Mast rad urban type Mast mod rad Colonoscopy w/lesion removal Colonoscopy w/lesion removal Mobilization of colon Partial removal of colon Partial removal of colon

6 44143 Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Removal of colon Removal of colon/ileostomy Colectomy w/ileoanal anast Colectomy w/ileoanal anast Removal of colon/ileostomy Removal of colon/ileostomy Colectomy w/ileoanal anast Colectomy w/neo-rectum pouch Removal of colon Laparo partial colectomy Lap colectomy part w/ileum Lap part colectomy w/stoma L colectomy/coloproctostomy L colectomy/coloproctostomy Laparo total proctocolectomy Lap colectomy w/proctectomy Laparo total proctocolectomy Lap mobil splenic fl add-on Total hysterectomy Total hysterectomy Partial hysterectomy Extensive hysterectomy Extensive hysterectomy Removal of pelvis contents Vaginal hysterectomy Vag hyst including t/o Vag hyst w/t/o & vag repair Vag hyst w/urinary repair Vag hyst w/enterocele repair Hysterectomy/revise vagina Hysterectomy/revise vagina Extensive hysterectomy Vag hyst complex Vag hyst incl t/o complex Vag hyst t/o & repair compl Vag hyst w/uro repair compl Vag hyst w/enterocele compl Other codes 00.10, 99.25, 99.28, 99.29, ICD-9 procedure codes for antineoplastic agent injection or infusion

7 Supplementary Table 3. ICD-9-CM codes for outcomes Condition ICD-9-CM codes Ischemic stroke 434, 436 Severe bleeding Intracranial bleeding 430, 431 Gastrointestinal bleeding 455.2, 455.5, 455.8, 456.0, , 530.7, , 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 533.6, 534.0, 534.2, 534.4, 534.6, , , , , , , , , , , , , , 569.3, , 578.0, 578.1, Other bleeding , 423.0, 432.0, 432.1, 432.9, 459.0, , , 599.7, 623.8, 626.2, 626.6, 719.1, , 784.7, 784.8, 786.3, VTE 415.1x, 451.1x, 453.2, 453.4x, 453.5x, 453.8, or Asthma , , , , , , , , , , , , , Supplementary Table 4. ICD-9-CM codes used to define comorbidities Condition ICD-9-CM codes Alcoholism 265.2, 291.1, 291.2, 291.3, 291.5, 291.6, 291.7, 291.8, 291.9, 303.0, 303.9, 305.0, 357.5, 425.5, 535.3, 571.0, 571.1, 571.2, 571.3, 980, V11.3 Hematological disorders 280, 281, 282, 283, 284, 285, 286, 287.1, 287.3, 287.4, 287.5, (Coagulopathy, anemia) Dementia 290.x, 294.1, Depression 296.2, 296.3, 296.5, 300.4, 309.x, 311.x Diabetes 250 Heart failure , , , , , , , , , , 425.4, 425.9, 428 Hypertension 401, 402, 403, 404, 405 Kidney disease , , , , , , , , , 582, 583.0, 583.1, 583.2, 583.3, 583.4, 583.5, 583.6, 583.7, 585, 586, 588.0, V42.0, V45.1, V56 Liver disease , , , , , , 070.6, 070.9, 456.0, 456.1, 456.2, 570, 571, 572.2, 572.3, 572.4, 572.5, 572.6, 572.7, 572.8, 573.3, 573.4, 573.8, 573.9, V42.7 Myocardial infarction 410, 412 Peripheral artery disease 440.0, 440.2, 440.9, 443.9

8 Supplemental Table 5. Adjusted hazard ratios (95% confidence intervals) stratified by cancer type comparing rivaroxaban users to matched warfarin users for the treatment of non-valvular atrial fibrillation in active cancer patients, MarketScan, Rivaroxaban User Matched Warfarin User HR (95% CI) p-value Breast # Events Person-years # Events Person-years Ischemic stroke ( ) 0.50 Severe bleeding (0.64, 3.11) 0.40 Other bleeding (0.26, 1.59) 0.34 VTE (0.32, 0.94) 0.03 Colon # Events Person-years # Events Person-years Ischemic stroke ( ) 0.34 Severe bleeding (0.20, 2.62) 0.63 Other bleeding (0.11, 1.45) 0.16 VTE (0.21, 0.96) 0.04 Lung # Events Person-years # Events Person-years Ischemic stroke ( ) 0.7 Severe bleeding (0.97, 3.75) 0.06 Other bleeding (1.00, 6.28) 0.05 VTE (0.25, 0.67) Prostate # Events Person-years # Events Person-years Ischemic stroke ( ) 0.25 Severe bleeding (0.02, 1.40) 0.1 Other bleeding (0.11, 1.97) 0.3 VTE (0.13, 0.81) 0.02 Other # Events Person-years # Events Person-years Ischemic stroke (0.32, 2.19) 0.71 Severe bleeding (0.67, 1.71) 0.78 Other bleeding (0.47, 1.32) 0.36 VTE (0.43, 0.82) 0.001

9 Supplemental Table 6. Adjusted hazard ratios (95% confidence intervals) stratified by cancer type comparing dabigatran users to matched warfarin users for the treatment of non-valvular atrial fibrillation in active cancer patients, MarketScan, Dabigatran User Matched Warfarin User HR (95% CI) p-value Breast # Events Person-years # Events Person-years Ischemic stroke (0.25, 1.96) 0.49 Severe bleeding (0.61, 2.93) 0.46 Other bleeding (0.17, 1.01) 0.05 VTE (0.09, 0.46) Colon # Events Person-years # Events Person-years Ischemic stroke (0.46, 4.78) 0.50 Severe bleeding (0.82, 3.20) 0.17 Other bleeding (0.12, 1.47) 0.17 VTE (0.13, 0.75) Lung # Events Person-years # Events Person-years Ischemic stroke (0.62, 6.55) 0.24 Severe bleeding (0.21, 1.92) 0.41 Other bleeding (0.06, 1.16) 0.08 VTE (0.12, 0.50) Prostate # Events Person-years # Events Person-years Ischemic stroke (0.10, 2.65) 0.43 Severe bleeding (0.17, 1.53) 0.23 Other bleeding (0.57, 5.14) 0.34 VTE (0.16, 1.02) 0.06 Other # Events Person-years # Events Person-years Ischemic stroke (0.36, 1.67) 0.51 Severe bleeding (0.58, 1.31) 0.51 Other bleeding (0.45, 1.17) 0.19 VTE (0.20, 0.50) < Adjusted for age, sex, CHA 2DS 2-VASc score, prevalent outcome and high-dimensional propensity score

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong